Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types.
Jake G MauleLani K ClintonRyon P GrafJinpeng XiaoGeoffrey R OxnardJeffrey S RossRichard S P HuangPublished in: Journal for immunotherapy of cancer (2022)
Our data suggest that 22C3 is the most sensitive PD-L1 IHC assay for tumor cell expression, followed by 28-8 and in turn by SP-142. These findings represent an additional factor for clinical teams to consider when deciding which PD-L1 IHC assay (and in turn which CDx-associated PD-L1 based immunotherapy) is most appropriate for each individual patient.